Evidence map›Paper›PMID 41387675›Full record

ArticleNature communications2025

Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors.

Marie-Edith Nepveu-Traversy, Malihe Hassanzadeh, Laurent Bruneau-Cossette, Élie Besserer-Offroy, Rebecca Brouillette, Sandra Morissette, Hassan Traboulsi, Karyn Kirby, Alexandre Murza, Jean-Michel Longpré and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marie-Edith Nepveu-TraversyDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0003-0936-6618
Malihe HassanzadehDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Laurent Bruneau-CossetteDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Élie Besserer-OffroyDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0002-7473-7043
Rebecca BrouilletteDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0002-5466-9653
Sandra MorissetteDomain Therapeutics NA Inc., Neomed Institute, Montreal, Quebec, Canada.
Hassan TraboulsiDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Karyn KirbyDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Alexandre MurzaDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
Jean-Michel LongpréDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0003-3985-2318
Billy BretonDomain Therapeutics NA Inc., Neomed Institute, Montreal, Quebec, Canada.
Fernand-Pierre GendronDepartment of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0002-4731-4352
Simon GaudreauImmune Biosolutions, Sherbrooke, Quebec, Canada.
Pierre-Luc BoudreaultDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada.ORCID http://orcid.org/0000-0002-2032-7970
Philippe SarretDepartment of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Quebec, Canada. Philippe.Sarret@USherbrooke.ca.ORCID http://orcid.org/0000-0002-7627-701X

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) FDN-148413
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) are critical to a variety of pathophysiological processes, making them attractive targets for the development of drugs or relevant diagnostic tools. Although GPCRs have been successfully targeted with small molecules, the production of reliable anti-GPCR antibodies remains a major challenge. To address this issue, we develop a strategy using macrocyclic peptides designed to mimic the three-dimensional structure of GPCR extracellular loops as immunogens and use the chicken, which is genetically distant from mammals, as an immunization host to produce antigen-specific antibodies. The high-affinity neurotensin receptor type 1 (NTS1), overexpressed in many types of human cancer and associated with poor prognosis, is used as a target. Rational design of macrocyclic epitope mimics and linker selection are achieved using modeling and predictive analysis software tools based on available NTS1 crystal structures. This study particularly highlights the critical role of the linker in peptide macrocyclization, which determines whether antibodies can exert antagonistic activity. Overall, this strategy represents a valuable asset to produce effective spatial anti-GPCR antibodies and holds promise for diagnostic and therapeutic applications.

Indexed as

AntibodiesPeptidesPeptides, CyclicReceptors, G-Protein-CoupledReceptors, NeurotensinAnimalsChickensDrug DesignEpitopesHumansMacrocyclic CompoundsModels, MolecularAntibodiesEpitopesMacrocyclic Compoundsneurotensin type 1 receptorPeptidesPeptides, CyclicReceptors, G-Protein-CoupledReceptors, Neurotensin

Identifiers

PMID41387675
PMCPMC12715230

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.